Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-alpha 2b: relation to response and HBV genotype

Sonneveld, Milan; Rijckborst, Vincent; Cakaloglu, Yilmaz; Simon, Krzysztof; Heathcote, E.; Tabak, ÖMER; Mach, Tomasz; Boucher, Charles; Hansen, Bettina; Zeuzem, Stefan; Janssen, Harry

doi:10.3851/imp1887

Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-alpha 2b: relation to response and HBV genotype

Sonneveld M. J., Rijckborst V., Cakaloglu Y., Simon K., Heathcote E. J., Tabak F., ...Daha Fazla

ANTIVIRAL THERAPY, cilt.17, sa.1, ss.9-17, 2012 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 17 Sayı: 1
Basım Tarihi: 2012
Doi Numarası: 10.3851/imp1887
Dergi Adı: ANTIVIRAL THERAPY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.9-17
Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
İstanbul Üniversitesi-Cerrahpaşa Adresli: Hayır

Özet

Background: On-treatment decline of serum hepatitis B surface antigen (HBsAg) may reflect the immunomodulatory effect of pegylated interferon (PEG-IFN) for hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB). We compared HBsAg decline across HBV genotypes between combined responders (HBeAg loss and HBV DNA < 10,000 copies/ml at week 78), HBeAg responders (HBeAg loss with HBV DNA > 10,000 copies/ml) and non-responders.